{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:56:06Z","timestamp":1791240966124,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13976-2","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T16:54:13Z","timestamp":1783616053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virological impact of the programmatic dolutegravir transition at Mildmay Hospital Uganda: a before-and-after cohort study with subgroup and trajectory analysis, 2016\u20132023"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0369-6151","authenticated-orcid":false,"given":"Roy Alia","family":"Asiku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Sserunjogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-4014","authenticated-orcid":false,"given":"Collins","family":"Ankunda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Kiwanuka Nakubulwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mwaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uthman","family":"Muluga Wandera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drake","family":"Musoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patience","family":"Kukundakwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-9911","authenticated-orcid":false,"given":"Ronald","family":"Mulebeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"13976_CR1","unstructured":"UNAIDS. Global AIDSU update 2023: The path that ends AIDS. Geneva: UNAIDS; 2023."},{"key":"13976_CR2","volume-title":"Uganda Population-based HIV Impact Assessment (UPHIA) 2020\/2021: Final Report","author":"Uganda Ministry of Health","year":"2024","unstructured":"Uganda Ministry of Health. Uganda Population-based HIV Impact Assessment (UPHIA) 2020\/2021: Final Report. Kampala: Ministry of Health; 2024."},{"key":"13976_CR3","volume-title":"Annual Joint AIDS Review Report FY 2022\/23: Final Report","author":"AIDS Uganda","year":"2023","unstructured":"Uganda AIDS, Commission. Annual Joint AIDS Review Report FY 2022\/23: Final Report. Kampala: Uganda AIDS Commission; 2023."},{"key":"13976_CR4","unstructured":"Uganda AIDS Commission. 2025 Uganda HIV and AIDS factsheet technical version: based on data ending 31st December 2024. Kampala: Uganda AIDS Commission; 2025."},{"issue":"5","key":"13976_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jama.2018.21167","volume":"321","author":"RW Eisinger","year":"2019","unstructured":"Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: Undetectable equals untransmittable. JAMA. 2019;321(5):451\u20132.","journal-title":"JAMA"},{"key":"13976_CR6","volume-title":"Consolidated Guidelines for Prevention and Treatment of HIV in Uganda","author":"Uganda Ministry of Health","year":"2016","unstructured":"Uganda Ministry of Health. Consolidated Guidelines for Prevention and Treatment of HIV in Uganda. Kampala: Ministry of Health; 2016."},{"issue":"12","key":"13976_CR7","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","volume":"32","author":"M Vitoria","year":"2018","unstructured":"Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551\u201361.","journal-title":"AIDS"},{"key":"13976_CR8","unstructured":"Uganda Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. Kampala; 2020."},{"key":"13976_CR9","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. Geneva: WHO; 2019."},{"issue":"9","key":"13976_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"issue":"9","key":"13976_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"C Kouanfack","year":"2019","unstructured":"Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816\u201326.","journal-title":"N Engl J Med"},{"issue":"10","key":"13976_CR12","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1016\/S2352-3018(20)30238-1","volume":"7","author":"A Calmy","year":"2020","unstructured":"Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results. Lancet HIV. 2020;7(10):e677\u201387.","journal-title":"Lancet HIV"},{"issue":"4","key":"13976_CR13","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa2101609","volume":"385","author":"NI Paton","year":"2021","unstructured":"Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385(4):330\u201341.","journal-title":"N Engl J Med"},{"issue":"9","key":"13976_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMe1909363","volume":"381","author":"DV Havlir","year":"2019","unstructured":"Havlir DV, Doherty MC. Global HIV treatment: turning headwinds to tailwinds. N Engl J Med. 2019;381(9):873\u20134.","journal-title":"N Engl J Med"},{"issue":"10","key":"13976_CR15","first-page":"1048","volume":"23","author":"JA Brown","year":"2022","unstructured":"Brown JA, Nsakala BL, Mokhele K, Rakuoane I, Muhairwe J, Urassa M, et al. Viral suppression after transition from NNRTI- to DTG-based ART: a prospective cohort study in Lesotho (DO-REAL study). HIV Med. 2022;23(10):1048\u201358.","journal-title":"HIV Med"},{"issue":"9","key":"13976_CR16","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/cid\/ciad390","volume":"77","author":"N Tschumi","year":"2023","unstructured":"Tschumi N, Lerotholi M, Motaboli L, Mokete M, Labhardt ND, Brown JA. Two-year outcomes of treatment-experienced adults after programmatic transitioning to dolutegravir: longitudinal data from the VICONEL HIV cohort in Lesotho. Clin Infect Dis. 2023;77(9):1318\u201321.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"13976_CR17","doi-asserted-by":"crossref","first-page":"ofad089","DOI":"10.1093\/ofid\/ofad089","volume":"10","author":"AJ Ntamatungiro","year":"2023","unstructured":"Ntamatungiro AJ, Muri L, Vanobberghen F, Klimkait T, Battegay M, Letang E, et al. Dolutegravir versus NNRTI-based ART in treatment-naive adults in Tanzania: a retrospective cohort study from KIULARCO. Open Forum Infect Dis. 2023;10(3):ofad089.","journal-title":"Open Forum Infect Dis"},{"key":"13976_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12981-024-00662-z","volume":"21","author":"RT Majula","year":"2024","unstructured":"Majula RT, Mweya CN. Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania. AIDS Res Ther. 2024;21:98.","journal-title":"AIDS Res Ther"},{"issue":"5","key":"13976_CR19","first-page":"527","volume":"90","author":"AL Esber","year":"2022","unstructured":"Esber AL, Coakley P, Iroezindu M, Bahemana E, Kibuuka H, Owuoth J, et al. Virologic impact of the dolutegravir transition in the AFRICOS cohort. J Acquir Immune Defic Syndr. 2022;90(5):527\u201333.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"13976_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1093\/cid\/ciab1006","volume":"75","author":"ML Romo","year":"2022","unstructured":"Romo ML, Edwards JK, Semeere AS, Musick BS, Urassa M, Odhiambo F, et al. Viral load status before switching to dolutegravir-containing ART and associations with HIV treatment outcomes in sub-Saharan Africa. Clin Infect Dis. 2022;75(4):630\u20137.","journal-title":"Clin Infect Dis"},{"key":"13976_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12889-026-26539-6","volume":"26","author":"C Ankunda","year":"2026","unstructured":"Ankunda C, Namasambi S, Kyomuhangi B, Emunyu J, Sserunjogi C, Nakaweesi J. Viral suppression and adverse events following antiretroviral therapy optimization among children and adolescents in Uganda, 2018\u20132023. BMC Public Health. 2026;26:786.","journal-title":"BMC Public Health"},{"issue":"1","key":"13976_CR22","first-page":"2637206","volume":"27","author":"C Ankunda","year":"2026","unstructured":"Ankunda C, Emunyu J, Namasambi S, Kyomuhangi B, Sserunjogi C, Mumbere I, et al. Longitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience. J Int AIDS Soc. 2026;27(1):2637206.","journal-title":"J Int AIDS Soc"},{"key":"13976_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1186\/s12879-025-11607-w","volume":"25","author":"C Ankunda","year":"2025","unstructured":"Ankunda C, Emunyu J, Namasambi S, Sserunjogi C, Kyomuhangi B, Mumbere I, et al. Prevalence of drug resistance mutations and their association with time to virological failure in people living with HIV in Uganda. BMC Infect Dis. 2025;25:1241.","journal-title":"BMC Infect Dis"},{"key":"13976_CR24","volume-title":"Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda","author":"Uganda Ministry of Health","year":"2023","unstructured":"Uganda Ministry of Health. Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda. Kampala: Ministry of Health; 2023."},{"issue":"6","key":"13976_CR25","doi-asserted-by":"publisher","first-page":"e0339549","DOI":"10.1371\/journal.pone.0339549","volume":"21","author":"JK Lubega","year":"2026","unstructured":"Lubega JK, Twesigye P, Migisha R, Bulage L, Kwesiga B, Nambuya P, et al. Trends and spatial distribution of low-level viremia among Ugandan children and adolescents, 2014\u20132023. PLoS ONE. 2026;21(6):e0339549. https:\/\/doi.org\/10.1371\/journal.pone.0339549.","journal-title":"PLoS ONE"},{"issue":"1","key":"13976_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2307\/1913646","volume":"46","author":"Y Mundlak","year":"1978","unstructured":"Mundlak Y. On the pooling of time series and cross section data. Econometrica. 1978;46(1):69\u201385.","journal-title":"Econometrica"},{"issue":"Suppl 2","key":"13976_CR27","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1097\/QAD.0000000000003082","volume":"35","author":"SM McCluskey","year":"2021","unstructured":"McCluskey SM, Pepperrell T, Hill A, Venter WDF, Gupta RK, Siedner MJ. Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. AIDS. 2021;35(Suppl 2):S127\u201335.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13976-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13976-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13976-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:35:02Z","timestamp":1791239702000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13976-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13976"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13976-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9567437\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical clearance was obtained from the Mildmay Uganda Research Ethics Committee (MUREC-2025-808). A waiver of individual informed consent was granted because the data were pre-existing, non-identifiable, and collected in the course of standard clinical care.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No individual-level data are presented.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1770"}}